You just read:

Can-Fite BioPharma Announces Top-Line Results of Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis

News provided by

Can-Fite BioPharma Ltd.

Dec 23, 2013, 07:00 ET